Clinical Trial

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 4, 2024 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-06-27.
Trial Details
NCT Number NCT05435248
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Advanced or Metastatic NSCLC
Enrollment 354 participants
Start Date 2022-03-02
Primary Completion 2025-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-04